Bank of New York Mellon Corp Purchases 6,328 Shares of XBiotech Inc. (NASDAQ:XBIT)

Bank of New York Mellon Corp raised its holdings in shares of XBiotech Inc. (NASDAQ:XBIT) by 7.5% during the fourth quarter, Holdings Channel reports. The fund owned 91,060 shares of the biopharmaceutical company’s stock after buying an additional 6,328 shares during the period. Bank of New York Mellon Corp’s holdings in XBiotech were worth $360,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of XBIT. Charles Schwab Investment Management Inc. raised its position in XBiotech by 7.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 4,298 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of XBiotech by 2.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock valued at $1,962,000 after acquiring an additional 5,500 shares in the last quarter. FMR LLC lifted its stake in XBiotech by 34.4% in the third quarter. FMR LLC now owns 28,992 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 7,420 shares during the period. Jane Street Group LLC bought a new stake in XBiotech in the third quarter valued at $86,000. Finally, MetLife Investment Management LLC purchased a new position in XBiotech during the 3rd quarter valued at $94,000. 55.70% of the stock is currently owned by institutional investors.

XBiotech Stock Performance

Shares of NASDAQ:XBIT opened at $3.10 on Friday. XBiotech Inc. has a 52-week low of $2.94 and a 52-week high of $9.96. The firm has a market capitalization of $94.51 million, a P/E ratio of -2.87 and a beta of 1.25. The stock has a 50 day moving average price of $3.33 and a 200-day moving average price of $5.36.

XBiotech (NASDAQ:XBIT) last released its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) EPS for the quarter.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.